Herantis H2 2023: Presented positive phase I data - Redeye

Redeye reviews the case of Herantis in the wake of progress with clinical candidate HER-096 and H2 report last week. We reiterate our positive view of the company.

Länk till analysen i sin helhet: https://www.redeye.se/research/989632/herantis-h2-2023-presented-positive-phase-i-data?utm_source=finwire&utm_medium=RSS